LB Pharmaceuticals Inc LBRX

Annual Quarterly

No annual revenue total was found in LB Pharmaceuticals Inc's SEC filings.

LB Pharmaceuticals Inc (LBRX) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$35.3 million. As of Sep 30, 2026 it held $403.8 million in cash and investments and $5.2 million in total debt.

Revenue
—
Net income (TTM)
$-141.19M
Operating cash flow (TTM)
$-143.31M
Free cash flow (TTM)
$-143.82M
EPS (TTM)
$-3.97
Dividend per share
None
Shares outstanding
28.67M
Net cash
$398.60M
as of Sep 30, 2026
Operating margin
—

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
LBRX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
New York, NY
SEC filer status
, Emerging growth company
SEC CIK
1691082
Former names
LB PHARMACEUTICALS INC. (until Dec 12, 2018)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Key figures

Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.

FY 2025
Dec 31, 2025
Net income
-$25.2M
Diluted EPS
-$3.13
Operating cash flow
-$35.2M
Free cash flow
-$35.3M
Total assets
$312.9M
Total liabilities
$11.6M
Stockholders' equity
$301.3M
Cash and investments
$295.2M
Total debt
$3.6M

Recent SEC filings

Form Description Filed Period
10-Q Quarterly report Nov 5, 2026 Sep 30, 2026
8-K Current report
Results of operations
 Nov 5, 2026 Nov 5, 2026
8-K Current report
Officer or director change, Regulation FD disclosure
 Sep 15, 2026 Sep 15, 2026
8-K Current report
Officer or director change, Regulation FD disclosure
 Sep 3, 2026 Sep 3, 2026
10-Q Quarterly report Aug 11, 2026 Jun 30, 2026
8-K Current report
Results of operations
 Aug 11, 2026 Aug 11, 2026

All 143 LB Pharmaceuticals Inc SEC filings

Source: SEC EDGAR filings. This is company-reported data, not investment advice.